ScinoPharm Taiwan Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ScinoPharm Taiwan.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 36.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Dec 2023 |
Recent future growth updates
Recent updates
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First
Apr 04
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Mar 14Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock
Feb 21ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares
Jan 25
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease
Jan 04Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Dec 14Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?
Nov 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 2,980 | 197 | 752 | 952 | 1 |
| 12/31/2023 | 3,186 | 287 | -54 | 231 | N/A |
| 9/30/2023 | 3,079 | 231 | -13 | 278 | N/A |
| 6/30/2023 | 3,124 | 261 | 189 | 449 | N/A |
| 3/31/2023 | 3,175 | 318 | 596 | 835 | N/A |
| 12/31/2022 | 3,264 | 353 | 524 | 774 | N/A |
| 9/30/2022 | 2,968 | 305 | 588 | 847 | N/A |
| 6/30/2022 | 2,917 | 254 | 392 | 702 | N/A |
| 3/31/2022 | 2,859 | 230 | 216 | 528 | N/A |
| 12/31/2021 | 2,762 | 243 | 189 | 510 | N/A |
| 9/30/2021 | 2,917 | 198 | 370 | 661 | N/A |
| 6/30/2021 | 3,021 | 266 | 516 | 759 | N/A |
| 3/31/2021 | 3,182 | 337 | 563 | 800 | N/A |
| 12/31/2020 | 3,083 | 282 | 763 | 946 | N/A |
| 9/30/2020 | 3,028 | 323 | 610 | 769 | N/A |
| 6/30/2020 | 2,954 | 279 | 576 | 712 | N/A |
| 3/31/2020 | 2,663 | 174 | 526 | 636 | N/A |
| 12/31/2019 | 2,893 | 217 | 683 | 789 | N/A |
| 9/30/2019 | 2,933 | 262 | 892 | 992 | N/A |
| 6/30/2019 | 3,067 | 312 | 1,198 | 1,306 | N/A |
| 3/31/2019 | 3,435 | 386 | 1,235 | 1,352 | N/A |
| 12/31/2018 | 3,524 | 443 | 1,105 | 1,232 | N/A |
| 9/30/2018 | 3,560 | 410 | 939 | 1,059 | N/A |
| 6/30/2018 | 3,591 | 434 | 833 | 990 | N/A |
| 3/31/2018 | 3,458 | 388 | 716 | 964 | N/A |
| 12/31/2017 | 3,516 | 422 | 561 | 972 | N/A |
| 9/30/2017 | 3,624 | 508 | N/A | 1,324 | N/A |
| 6/30/2017 | 3,767 | 567 | N/A | 1,191 | N/A |
| 3/31/2017 | 3,929 | 657 | N/A | 1,306 | N/A |
| 12/31/2016 | 4,031 | 659 | N/A | 1,665 | N/A |
| 9/30/2016 | 4,059 | 707 | N/A | 1,410 | N/A |
| 6/30/2016 | 4,050 | 736 | N/A | 1,282 | N/A |
| 3/31/2016 | 3,998 | 694 | N/A | 1,467 | N/A |
| 12/31/2015 | 3,955 | 635 | N/A | 1,045 | N/A |
| 9/30/2015 | 3,775 | 445 | N/A | 1,375 | N/A |
| 6/30/2015 | 3,795 | 371 | N/A | 1,230 | N/A |
| 3/31/2015 | 3,980 | 432 | N/A | 637 | N/A |
| 12/31/2014 | 4,098 | 484 | N/A | 888 | N/A |
| 9/30/2014 | 4,572 | 744 | N/A | 246 | N/A |
| 6/30/2014 | 4,809 | 875 | N/A | 730 | N/A |
| 3/31/2014 | 5,000 | 1,089 | N/A | 925 | N/A |
| 12/31/2013 | 5,088 | 1,273 | N/A | 939 | N/A |
| 9/30/2013 | 5,168 | 1,431 | N/A | 1,672 | N/A |
| 6/30/2013 | 5,213 | 1,504 | N/A | 1,377 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1789's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 1789's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 1789's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1789's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 1789's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1789's Return on Equity is forecast to be high in 3 years time